MC4R Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for MC4R is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
52 Direct drug records from Target & Disease MCP | 31 Development records in target context | 47 Disease associations captured | 47 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
Biology signal
MC4R is a central component of the leptin-melanocortin pathway. Target & Disease MCP describes its role in hypothalamic anorexogenic signaling, cAMP activation, appetite suppression, and energy balance through POMC-derived melanocortins and AGRP antagonism.
Validation evidence
The evidence base is focused and genetically anchored: 52 drug records, 31 development records, 47 disease associations, and 47 clinical trial records. Trials in Bardet-Biedl syndrome, severe genetic obesity, and setmelanotide-related use cases show clinical traction.
Competition and differentiation
MC4R is not a general obesity target in the same way as GLP1R. Its strongest position is genetically or pathway-defined obesity, where patient selection, diagnosis, long-term safety, and access programs drive value.
IP and partnering view
IP review should cover agonist chemistry, genetic-obesity indication claims, expanded-access strategy, and diagnostic companion workflows. Partnerships may require both drug development and patient-identification infrastructure.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 47 registered trial records connected to MC4R. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| REAL-MC4: real-world effects of MC4R agonist therapy in BBS and severe genetic obesity | Phase 4 | Recruiting |
| Setmelanotide to treat obesity in pseudohypoparathyroidism type 1a | Phase 2 | Not yet recruiting |
| Expanded access to mifomelatide for cachexia in advanced PDAC | Not Applicable | No longer available |
R&D Strategy Recommendation
MC4R is strategically attractive in precision obesity. Use MCP workflows to map genotype-defined populations, real-world evidence, and label-expansion opportunities rather than treating it as a broad obesity play.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
